Lung Cancer News

The combination of ipilimumab and stereotactic body radiotherapy delivered sequentially demonstrated promising response rates and survival in patients with solid tumors and metastatic lung or liver lesions, according to prospective phase 2 study results presented at the American Society for Radiation Oncology Annual Meeting.

CHICAGO — Ensartinib shows promise for the treatment of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, Makenzi Evangelist, MD, said at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.

Patients with HIV who adhere to antiretroviral therapy but smoke are significantly more likely to die from lung cancer than from AIDS-related causes; therefore, smoking cessation should be a priority in HIV care, according to research published in JAMA Internal Medicine.

CHICAGO — Smoking status did not affect biomarkers, immune-related adverse events or survival among patients treated with anti-PD-1 therapy for non-small cell lung cancer, according to a study presented at the International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.

CHICAGO — Further investigation is warranted regarding treatment with stereotactic ablative radiotherapy in combination with anti-PD-1 therapy for patients with advanced lung cancer, Makenzi Evangelist, MD, said at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.

CHICAGO — Tocilizumab appeared to be a viable therapeutic option for patients with lung cancer who experienced an immune-mediated adverse event following treatment with PD-1 checkpoint blockade, according to study results presented at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.

CHICAGO — Ensartinib appeared safe and effective in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to study results presented at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.

CHICAGO — Combination therapy with dabrafenib and trametinib conferred longer survival than docetaxel for patients with BRAF V600E-positive non-small cell lung cancer, according to results of an adjusted indirect comparison presented at the International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.

CHICAGO — A majority of heavy smokers enrolled in University of Arkansas’s lung cancer screening program quit or decreased their tobacco use while undergoing tobacco cessation counseling, according to study results presented at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.

CHICAGO — The addition of nintedanib to pemetrexed/cisplatin appeared safe and effective for the treatment of patients with malignant pleural mesothelioma, according to results from the LUME-Meso trial presented at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.